Five-Year OS Based on the IPI
| IPI Score . | Clinical Risk Group . | 5-Year OS All Cases % (no. of patients) . | 5-Yr OS T/Null % (no. of patients) . |
|---|---|---|---|
| 0, 1 | Low | 85 (29) | 84 (27) |
| 2 | Low-intermediate | 69 (18) | 75 (10) |
| 3 | High-intermediate | 37 (11) | 56 (8) |
| 4, 5 | High | 18 (12) | 18 (11) |
| Total | 65 (70) | 67 (57) |
| IPI Score . | Clinical Risk Group . | 5-Year OS All Cases % (no. of patients) . | 5-Yr OS T/Null % (no. of patients) . |
|---|---|---|---|
| 0, 1 | Low | 85 (29) | 84 (27) |
| 2 | Low-intermediate | 69 (18) | 75 (10) |
| 3 | High-intermediate | 37 (11) | 56 (8) |
| 4, 5 | High | 18 (12) | 18 (11) |
| Total | 65 (70) | 67 (57) |
Log-rank analysis of the 5-year OS for either the entire cohort (P < .0001) or the T-cell/null immunophenotype cases (P = .006) based on the IPI score was significant.